PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
4.32
Current Ratio > 1.5x TRAW's 0.81. David Dodd would confirm if this surplus liquidity is put to good use.
4.32
Quick Ratio > 1.5x TRAW's 0.81. David Dodd would verify if the company can handle unexpected shortfalls much better.
4.19
Cash Ratio above 1.5x TRAW's 0.69. David Dodd would confirm if this large cash position offsets potential expansions or acquisitions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.